Separation and determination of liposomal and non-liposomal daunorubicin from the plasma of patients treated with Daunoxome
Authors:
- 9 May 2001
- journal article
- Published by Elsevier in Journal of Chromatography B: Biomedical Sciences and Applications
- Vol. 757 (2) , 257-267
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicinBritish Journal of Cancer, 1999
- Liposome‐encapsulated daunorubicin for PGP‐related multidrug resistanceBritish Journal of Haematology, 1999
- Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma.Journal of Clinical Oncology, 1998
- The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi’s sarcoma patients treated with pegylated liposomal doxorubicinAnnals of Oncology, 1998
- Polyethylene Glycol-Liposomal DoxorubicinDrugs, 1997
- Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumventionBritish Journal of Pharmacology, 1996
- Failure of liposomal encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cellsEuropean Journal of Cancer, 1995
- Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin.Journal of Clinical Oncology, 1995
- Phase I and pharmacologie study of liposomal daunorubicin (DaunoXome)Investigational New Drugs, 1994
- Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.Proceedings of the National Academy of Sciences, 1981